Comparison of Rocuronium Induced Neuromuscular Blockade in Late Second Trimester Pregnant and Non-pregnant Women
NCT ID: NCT04253093
Last Updated: 2020-02-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
50 participants
OBSERVATIONAL
2019-08-01
2020-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Magnesium Sulfate on Onset and Duration of Low Dose Rocuronium
NCT02100293
The Effect of Deep Neuromuscular Blockade on Requirement of Intravenous Anesthetic Agent
NCT03890406
Sugammadex-Induced Clenching During Neuromuscular Blockade Reversal
NCT06962007
Effects of Repeated Intravenous Anesthesia With Propofol on the Postoperative Neurological Function of Patients Undergoing Hysteroscopic Surgery
NCT05297682
Study on the Level of Neuromuscular Blockade
NCT03782233
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Rocuronium is a commonly used neuromuscular blocking drug categorized as FDA category B. Rocuronium is widely used for pregnant women. Previous studies have evaluated the onset and duration of rocuronium in postpartum women. Lately, the investigators have evaluated the onset and duration of rocuronium in early second trimester pregnant women and the duration was significantly longer in early second trimester women compared to non-pregnant women.
Since there is little research on the onset and duration of rocuronium in the late second trimester pregnant women, the investigators planned the present research.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* renal disease
* diabetes mellitus
* asthma
* allergic to specific drugs
* BMI\>30 or \<18
20 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hallym University Kangnam Sacred Heart Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Choi Eun MI
professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eunmi Choi
Role: STUDY_CHAIR
professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kangnam sungshim hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jun In-Jung
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-05-008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.